Neoadjuvant therapy
Case Report: pCR to NAC + Pembro in High Risk Basal-type BC
Cureus, part of Springer Nature Author: Jiang et al.
Read MoreImproved Neoadjuvant Chemo Prediction for HR+HER2- ESBC with MP High 2
21st Bossche Mamma Congress 2024, P07 Presenter: O'Shaughnessy et al.
Read MoreElucidating the immune active state of HR+HER2- MammaPrint High 2
Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer
Read MoreNeoadjuvant CT Recommendations in Black women – SSO 2024
SSO 2024 Author: Solis-Pomales et al.
Read MoreNeoadjuvant Endocrine Treatment outcomes – The Breast 2024
The Breast 75 (2024) 103726 Presenter: van Olmen et al.
Read MoreNeoadjuvant CT & Immunotherapy in HR+/HER2-negative breast cancer
Journal of Clinical Oncology, April 9, 2024 Presenter: Rios-Hoyo et al.
Read MoreEBCC 2024: The New Era of Genomic Testing in Early Stage Breast Cancer
EBCC 2024, Oral Presentation Presenter: Dr. Caroline Drukker
Read MoreMammaPrint + BluePrint predict anthracycline chemosensitivity, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 36 Authors: Audeh et al.
Read MorePrediction of chemotherapy benefit by MammaPrint®, Audeh et al., Miami Breast 2024
Miami Breast 2024, Poster 29 Authors: Audeh et al.
Read MoreMammaPrint + BluePrint predict pCR after NCT-FLEX, O’Shaughnessy et al., SABCS 2023 Abstract
SABCS 2023, PO5-15-04 Authors: O'Shaughnessy et al.
Read More
